Key opinion leaders (KOLs) were "giddy" about Ardelyx Inc.'s phase III data with tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis, said CEO Mike Raab, and the company is putting together plans for another experiment that could lead to approval.